"Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial." New England Journal of Medicine, vol
Studies have shown that slowing down gut transit decreases fecal sulfate, meaning more sulfate remains available in the gut for bacterial metabolism (and, thus, hydrogen sulfide gas production!)
How Are Insurance Policies Changing for My GLP1 Medication in 2026
They provide a safe and simple boost for anyone wishing to jumpstart their weight loss
Immune cell-derived cytokines contribute to obesity-related inflammation, fibrogenesis and metabolic deregulation in human adipose tissue
Ileus or bowel obstruction Gallbladder disease and gallstones Pancreatitis and pancreatic injury Dehydration , electrolyte imbalances , and kidney strain Weight loss outside expected ranges or malnutrition in some cases, including individuals using these drugs, such as Ozempic, for weight loss Vision loss and rare visual conditions such as NAION , with some plaintiffs reporting symptoms consistent with naion even before clear diagnosis Concerns over thyroid Ccell tumors noted in animal studies The lawsuits generally claim that manufacturers, including Novo Nordisk, failed to provide adequate warnings about drugs like Ozempic, promoted offlabel use for weight loss without proper risk disclosures, and did not update labels or prescriber communications quickly enough as reports of side effects and other injuries came in